| Eric M Luitweiler, MD | |
|
515 Minor Ave Ste 300, Seattle, WA 98104-2133 | |
| (206) 320-6565 | |
| (206) 386-9648 |
| Full Name | Eric M Luitweiler |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Nephrology |
| Location | 515 Minor Ave Ste 300, Seattle, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093202574 | NPI | - | NPPES |
| 2188886 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | MD61167673 (Washington) | Primary |
| 207R00000X | Internal Medicine | MD61167673 (Washington) | Secondary |
| Entity Name | Swedish Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689612954 PECOS PAC ID: 0244138196 Enrollment ID: O20031230000187 |
News Archive
Until recently, physicians had generally assumed that older adults benefit from keeping their blood pressure below 140/90 mmHg. However, researchers from Charité - Universitätsmedizin Berlin have now found that this assumption does not apply to all patients with high blood pressure.
Prescription drugs and their dosages may be standardized, but not every patient reacts to a medicine in the same way. The personal genetic characteristics of individuals and populations can explain why a specific prescription successfully treats one patient and not another, so medical researchers are adopting the new approach called "personalized medicine" and a Tel Aviv University lab is leading the way.
Kimberly-Clark Corporation and I-Flow Corporation, a leading healthcare company that develops and markets technically advanced, low-cost drug delivery systems and innovative products for post-surgical pain relief and surgical site care, today announced a definitive agreement whereby I-Flow will be acquired in a cash tender offer for approximately $324 million on a fully diluted basis.
Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis. OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy.
Titan Enterprises announces MetraFlow - an exciting new addition to the company's expanding ultrasonic flowmeter range.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eric M Luitweiler, MD Po Box 25608, Salt Lake City, UT 84125-0608 Ph: (206) 320-4476 | Eric M Luitweiler, MD 515 Minor Ave Ste 300, Seattle, WA 98104-2133 Ph: (206) 320-6565 |
News Archive
Until recently, physicians had generally assumed that older adults benefit from keeping their blood pressure below 140/90 mmHg. However, researchers from Charité - Universitätsmedizin Berlin have now found that this assumption does not apply to all patients with high blood pressure.
Prescription drugs and their dosages may be standardized, but not every patient reacts to a medicine in the same way. The personal genetic characteristics of individuals and populations can explain why a specific prescription successfully treats one patient and not another, so medical researchers are adopting the new approach called "personalized medicine" and a Tel Aviv University lab is leading the way.
Kimberly-Clark Corporation and I-Flow Corporation, a leading healthcare company that develops and markets technically advanced, low-cost drug delivery systems and innovative products for post-surgical pain relief and surgical site care, today announced a definitive agreement whereby I-Flow will be acquired in a cash tender offer for approximately $324 million on a fully diluted basis.
Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis. OCR-002 recently received Orphan Drug status and Fast Track designation by the United States Food and Drug Administration for the treatment of hyperammonemia (excessive ammonia levels) and resultant Hepatic encephalopathy.
Titan Enterprises announces MetraFlow - an exciting new addition to the company's expanding ultrasonic flowmeter range.
› Verified 3 days ago
Sandhya Ramanathan Panch, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Stephen A Lopez, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 925 Seneca St, Seattle, WA 98101 Phone: 206-341-0860 | |
Dr. Susan Hunt, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: Uwmc Department Of Medicine, Box 356429, Seattle, WA 98195 Phone: 206-221-7993 Fax: 206-221-8732 | |
Timothy William Menza, MD, PHD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-520-5000 | |
Dr. Vinay Gupta, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1100 9th Ave, Seattle, WA 98101 Phone: 206-223-6980 Fax: 206-223-6982 | |
Dr. Maria Ann Corcorran, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1550 N 115th St, Seattle, WA 98133 Phone: 206-520-5000 | |
Vyshak Alva Venur, M.D Nephrology Medicare: Accepting Medicare Assignments Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5700 |